Evidence map›Paper›PMID 23715902›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2013

[¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches.

Zhangjie Su, Karl Herholz, Alexander Gerhard, Federico Roncaroli, Daniel Du Plessis, Alan Jackson, Federico Turkheimer, Rainer Hinz

Open access · hybridAbstract readComparative Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Immune cell identity behind the KMagnetic resonance imaging · 2023
    Article
  3. Review
  4. TSPO PET signal using [European journal of nuclear medicine and molecular imaging · 2023
    Article
  5. Review
  6. Potential of [Pharmaceutics · 2022
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Supervised clustering for TSPO PET imaging.European journal of nuclear medicine and molecular imaging · 2021
    Review
  12. Imaging of the glioma microenvironment by TSPO PET.European journal of nuclear medicine and molecular imaging · 2021
    Review
  13. NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  14. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.European journal of nuclear medicine and molecular imaging · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhangjie SuWolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, Manchester, UK. zhangjie.su@manchester.ac.uk
Karl Herholz
Alexander Gerhard
Federico Roncaroli
Daniel Du Plessis
Alan Jackson
Federico Turkheimer
Rainer Hinz
University of Manchester · GBImperial College London · GBSalford Royal NHS Foundation Trust · GBWellcome Centre for Human Neuroimaging · GB

Funding

Cancer Research UK 16465Cancer Research UK 18097Medical Research Council G0900891Medical Research Council G1100809/1
6 · The paper itself

Abstract

purposeTranslocator protein (TSPO) is a biomarker of neuroinflammation that can be imaged by PET using [¹¹C]-(R)PK11195. We sought to characterize the [¹¹C]-(R)PK11195 kinetics in gliomas of different histotypes and grades, and to compare two reference tissue input functions (supervised cluster analysis versus cerebellar grey matter) for the estimation of [¹¹C]-(R)PK11195 binding in gliomas and surrounding brain structures.

methodsTwenty-three glioma patients and ten age-matched controls underwent structural MRI and dynamic [¹¹C]-(R)PK11195 PET scans. Tissue time-activity curves (TACs) were extracted from tumour regions as well as grey matter (GM) and white matter (WM) of the brains. Parametric maps of binding potential (BPND) were generated with the simplified reference tissue model using the two input functions, and were compared with each other. TSPO expression was assessed in tumour tissue sections by immunohistochemistry.

resultsThree types of regional kinetics were observed in individual tumour TACs: GM-like kinetics (n=6, clearance of the tracer similar to that in cerebellar GM), WM-like kinetics (n=8, clearance of the tracer similar to that in cerebral WM) and a form of mixed kinetics (n=9, intermediate rate of clearance). Such kinetic patterns differed between low-grade astrocytomas (WM-like kinetics) and oligodendrogliomas (GM-like and mixed kinetics), but were independent of tumour grade. There was good agreement between parametric maps of BPND derived from the two input functions in all controls and 10 of 23 glioma patients. In 13 of the 23 patients, BPND values derived from the supervised cluster input were systematically smaller than those using the cerebellar input. Immunohistochemistry confirmed that TSPO expression increased with tumour grade.

conclusionThe three types of [¹¹C]-(R)PK11195 kinetics in gliomas are determined in part by tracer delivery, and indicated that kinetic analysis is a valuable tool in the study of gliomas with the potential for in vivo discrimination between low-grade astrocytomas and oligodendrogliomas. Supervised cluster and cerebellar input functions produced consistent BPND estimates in approximately half of the gliomas investigated, but had a systematic difference in the remainder. The cerebellar input is preferred based on theoretical and practical considerations.

Indexed as

AmidesBrain NeoplasmsCase-Control StudiesGliomaIsoquinolinesPositron-Emission TomographyProtein BindingRadiopharmaceuticalsReceptors, GABAReference StandardsTissue DistributionAmidesIsoquinolines(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamideRadiopharmaceuticalsReceptors, GABATSPO protein, human

Identifiers

PMID23715902
PMCPMC3738844
OpenAlexW2164024602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.